Relief Therapeutics Holding SA announced an extension of its exclusive, long-term agreement with Pentec Health Inc. broadening the distribution of PKU GOLIKE®? in the U.S. Pentec Health is a leading provider of healthcare services for complex care challenges, including clinical nutrition and specialty care, and the exclusive distributor of PKU GOLIke®? in the U. S. The acquisition of ZOIA Pharma by Pentec Health provides patients living with PKU who purchase products through ZOIA Pharma access to PKU GOLIKE??.

This enables Relief Therapeutics to broaden distribution of PKU GOL IKE®? across an expanded commercial payor base, ensuring more patients living with PKU will have access to the PKUGOLIKE®? family of products to help them manage their condition.

According to the National PKU Alliance, there are approximately 16,500 people living with PKU do not have the ability to metabolize phenylalanine (Phe), which is found in many foods, and therefore require supplementation of amino acid-based medical foods to prevent protein deficiency and optimize metabolic control.